Rep. Cuellar Announces Lower Prescription Drug Costs

Dr. Cuellar Voted to Pass the Inflation Reduction Act (IRA), Which Enabled Negotiations to Lower Costs for Prescription Drugs Under Medicare

Translate to Spanish or other 102 languages!

Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
- Advertisement -

Washington, DC – Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare.

“I voted to pass the IRA, which has lowered health care and prescription drug costs for Americans. It not only capped the monthly cost of insulin for seniors on Medicare at $35 but also limited out-of-pocket prescription drug costs for seniors,” said Dr. Cuellar, a senior member of the House Appropriations Committee. “Furthermore, due to the IRA, the administration was able to negotiate lower costs for ten of the most expensive prescription drugs under Medicare. This is a historic achievement and will bring needed relief to everyday Americans. I voted for the Inflation Reduction Act to ensure that Americans get the help they need. I will continue to support efforts to reduce health care costs.” 

The ten drugs negotiated down include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp.

- Advertisement -

Through the IRA, more than 100,000 Texans on Medicare are saving on average $441 per year through the insulin price cap alone.  It caps insulin costs at $35 per month for those on Medicare and limits out-of-pocket prescription drug costs to $2,000 per year.

1,323,430 Texans will save $400 per year on average through the IRA’s $2,000 out-of-pocket cap, which will begin in 2025.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

The Impact of Physical Activity on Parkinson’s Decline

For 68-year-old Robert Kennedy, a retired Florida Power and Light foreman, the secret to managing his Parkinson symptoms is movement.

FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment 

The U.S. Food and Drug Administration approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.

Social Security Administration Corrects Millions of Records in Major Database Cleanup

The Social Security Administration (SSA) announced on October 20, 2026, that it has corrected millions of Social Security number records in what the agency describes as its most comprehensive record-integrity initiative in 91 years.

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.
- Advertisement -